Lipidil (Fenofibrate (Nanonised))

Fenofibrate activates the nuclear receptor PPARα, which regulates genes involved in fatty‑acid oxidation and lipoprotein metabolism. This activation enhances the breakdown of triglycerides, reduces hepatic triglyceride synthesis, and promotes clearance of triglyceride‑rich particles, leading to lower plasma triglyceride concentrations.

The specific dose of Lipidil is determined by the prescribing healthcare professional based on the patient’s clinical condition, laboratory values, and response to therapy. Dosage adjustments may be required for renal or hepatic impairment, and the prescriber will provide individualized instructions.

The safety of fenofibrate in pregnancy and lactation has not been definitively established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To place an order, submit an enquiry on the Lipidil product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details, and any necessary import documentation.

Compared with statins, fenofibrate primarily lowers triglycerides and modestly raises HDL‑cholesterol, whereas statins are more potent at reducing LDL‑cholesterol. Fenofibrate is often used when triglyceride reduction is the primary goal or as an adjunct to statin therapy, but combined use requires careful monitoring for muscle toxicity.

Lipidil should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture and direct light to maintain stability and potency throughout its shelf life.

Lipidil is taken orally, usually with a meal to enhance absorption. The tablet should be swallowed whole with water and not chewed or crushed unless specifically directed by a healthcare professional.

The most serious risks include rhabdomyolysis (especially when combined with statins), severe hepatic dysfunction, acute pancreatitis, and rare but severe skin reactions such as Stevens‑Johnson syndrome. Patients should report unexplained muscle pain, dark urine, jaundice, or skin eruptions promptly.

Lipidil is contraindicated in individuals with known hypersensitivity to fenofibrate or other fibrates, those with active gallbladder disease, severe renal impairment, and patients with pre‑existing severe liver disease. It should also be avoided in patients taking gemfibrozil due to a high risk of muscle toxicity.